MCID: OCL009
MIFTS: 56

Ocular Cancer

Categories: Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Ocular Cancer

MalaCards integrated aliases for Ocular Cancer:

Name: Ocular Cancer 12 15
Eye Carcinoma 12 15 73
Eye Neoplasms 44 73
Eye Cancer 55 43
Malignant Eye Neoplasm 12
Neoplasm of Eye Proper 12
Malignant Tumor of Eye 73
Carcinoma of Eye 12
Ocular Carcinoma 12
Neoplasm of Eye 12
Eye Neoplasm 12
Ocular Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2174 DOID:295
ICD9CM 35 190.8
MeSH 44 D005134
NCIt 50 C3030 C6079

Summaries for Ocular Cancer

MedlinePlus : 43 Cancer of the eye is uncommon. It can affect the outer parts of the eye, such as the eyelid, which are made up of muscles, skin and nerves. If the cancer starts inside the eyeball it's called intraocular cancer. The most common intraocular cancers in adults are melanoma and lymphoma. The most common eye cancer in children is retinoblastoma, which starts in the cells of the retina. Cancer can also spread to the eye from other parts of the body. Treatment for eye cancer varies by the type and by how advanced it is. It may include surgery, radiation therapy, freezing or heat therapy, or laser therapy.

MalaCards based summary : Ocular Cancer, also known as eye carcinoma, is related to melanoma, uveal and grade iii astrocytoma, and has symptoms including eye manifestations An important gene associated with Ocular Cancer is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 An ocular cancer that has material basis in abnormally proliferating cells, derives from epithelial cells and arises_from the tissues that cover structures located in the eye.

Wikipedia : 76 Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer).... more...

Related Diseases for Ocular Cancer

Diseases related to Ocular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 melanoma, uveal 30.3 CDK4 CDKN2A GNAQ MDM2
2 grade iii astrocytoma 30.1 CDK4 CDKN2A MDM2 TP53
3 supratentorial cancer 30.1 CDKN2A MDM2 SOX2 TP53
4 central nervous system cancer 30.1 CDKN2A MYC SOX2 TP53
5 medulloblastoma 29.8 BRCA2 CCND1 CDK4 CDK6 MYC SOX2
6 brain cancer 29.8 ABCG2 BRCA2 CDK4 CDKN1A MDM2 MYC
7 unilateral retinoblastoma 29.7 RB1 RBL1
8 teratoma 29.6 POU5F1 SOX2 TP53
9 ewing sarcoma 29.3 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
10 glioblastoma 29.2 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
11 retinoblastoma 29.2 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
12 retinal cancer 29.1 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
13 eye carcinoma in situ 12.0
14 encephalocraniocutaneous lipomatosis 10.9
15 intraocular lymphoma 10.9
16 vulvar adenocarcinoma 10.3 RB1 TP53
17 zika virus infection 10.3 MDM2 TP53
18 spindle cell lipoma 10.3 CDK4 MDM2 RB1
19 malignant fibrous histiocytoma of bone 10.3 CDK4 MDM2 MYC
20 ring chromosome 7 10.3 CDK4 MDM2 TP53
21 glioblastoma proneural subtype 10.3 CDK4 CDK6
22 breast papillomatosis 10.3 CCND1 CDKN2A
23 undifferentiated embryonal sarcoma of the liver 10.3 CDK4 MDM2
24 infiltrating angiolipoma 10.3 CDK4 CDKN2A MDM2
25 hepatic angiomyolipoma 10.3 MYC RB1
26 atypical lipomatous tumor 10.3 CDK4 CDKN2A MDM2
27 venous hemangioma 10.3 MYC POU5F1 SOX2
28 periosteal osteogenic sarcoma 10.3 CDK4 MDM2 TP53
29 small cell sarcoma 10.3 CDK4 MDM2 TP53
30 well-differentiated liposarcoma 10.3 CDK4 CDKN2A MDM2
31 ewing's family of tumors 10.3 CDK4 CDKN2A RB1
32 embryonal sarcoma 10.3 CDK4 MDM2 TP53
33 fallopian tube carcinoma 10.3 BRCA2 MYC TP53
34 male reproductive system disease 10.3 CCND1 MYC TP53
35 actinic cheilitis 10.3 CDKN1A MDM2 TP53
36 synchronous bilateral breast carcinoma 10.3 BRCA2 CCND1 TP53
37 lip cancer 10.3 CDKN1A MDM2 TP53
38 megaesophagus 10.3 CDKN2A MYC TP53
39 connective tissue cancer 10.3 CDK4 MDM2 TP53
40 glycogen-rich clear cell breast carcinoma 10.3 BRCA2 CDKN2A TP53
41 tonsil squamous cell carcinoma 10.3 CCND1 CDKN2A
42 mutagen sensitivity 10.2 BRCA2 CCND1 TP53
43 myxoid liposarcoma 10.2 CDK4 MDM2 TP53
44 periosteal chondrosarcoma 10.2 CDK4 CDKN2A MDM2 RB1
45 fibrosarcoma of bone 10.2 CDK4 CDKN2A MDM2 MYC
46 gallbladder adenoma 10.2 CDKN2A RB1
47 endometrial squamous cell carcinoma 10.2 CCND1 CDK6 CDKN2A
48 leiomyosarcoma 10.2 CDK4 MDM2 TP53
49 male reproductive organ cancer 10.2 CCND1 MYC TP53
50 ductal carcinoma in situ 10.2 BRCA2 CCND1 TP53

Graphical network of the top 20 diseases related to Ocular Cancer:



Diseases related to Ocular Cancer

Symptoms & Phenotypes for Ocular Cancer

UMLS symptoms related to Ocular Cancer:


eye manifestations

GenomeRNAi Phenotypes related to Ocular Cancer according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.46 CDK2 MDM2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.46 CDK2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.46 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.46 CDK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.46 MDM2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.46 MDM2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.46 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.46 CDK2 MDM2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.46 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.46 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.46 MDM2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.46 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.46 MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.46 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.46 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.46 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.46 MYC
18 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.46 CCND1 CDK2 MDM2 MYC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.46 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.46 CDK2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.46 CDK2 MDM2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.46 CDK2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.46 CDK2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.46 MDM2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.46 MYC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.46 CDK2
27 Decreased viability GR00221-A-1 10.36 CDK6 CDKN1B CDKN2A MYC RBL1 RBL2
28 Decreased viability GR00221-A-2 10.36 CDK6 RBL1
29 Decreased viability GR00221-A-3 10.36 CDKN2A MYC
30 Decreased viability GR00221-A-4 10.36 CDK6 CDKN2A SOX2
31 Decreased viability GR00301-A 10.36 CDK6
32 Decreased viability GR00402-S-2 10.36 CDK6 CDKN1B CDKN2A MYC RBL1 RBL2
33 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.13 BRCA2 CDK2 CDKN1A CDKN2A IL2 RB1
34 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.13 BRCA2 CDK2 CDKN1A CDKN2A IL2 RB1
35 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.63 BRCA2 CDK2 CDKN1A CDKN1B MDM2 TP53
36 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRCA2 CDK2 CDK4 CDK6 RBL1

MGI Mouse Phenotypes related to Ocular Cancer:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
2 endocrine/exocrine gland MP:0005379 10.58 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
3 behavior/neurological MP:0005386 10.56 ABCG2 BRCA2 CCND1 CDK4 CDKN1A CDKN1B
4 growth/size/body region MP:0005378 10.55 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
5 cardiovascular system MP:0005385 10.53 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
6 hematopoietic system MP:0005397 10.53 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
7 homeostasis/metabolism MP:0005376 10.52 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
8 embryo MP:0005380 10.51 BRCA2 CDK2 CDK4 CDK6 CDKN1A CDKN1B
9 immune system MP:0005387 10.51 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
10 integument MP:0010771 10.5 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDKN1A
11 digestive/alimentary MP:0005381 10.49 BRCA2 CCND1 CDK4 CDKN1A CDKN1B CDKN2A
12 mortality/aging MP:0010768 10.49 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
13 neoplasm MP:0002006 10.41 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14 craniofacial MP:0005382 10.4 CCND1 CDKN1A CDKN1B E2F4 GNAQ MDM2
15 liver/biliary system MP:0005370 10.37 ABCG2 CDK2 CDK4 CDK6 CDKN1A CDKN1B
16 nervous system MP:0003631 10.36 ABCG2 BRCA2 CCND1 CDK4 CDKN1A CDKN1B
17 muscle MP:0005369 10.34 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
18 hearing/vestibular/ear MP:0005377 10.28 CDKN1A CDKN1B E2F4 GNAQ MYC RB1
19 normal MP:0002873 10.25 ABCG2 BRCA2 CCND1 CDK4 E2F4 GNAQ
20 reproductive system MP:0005389 10.21 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
21 limbs/digits/tail MP:0005371 10.19 BRCA2 CDKN1A GNAQ MDM2 MYC RB1
22 adipose tissue MP:0005375 10.18 ABCG2 CDKN1A CDKN1B MYC RB1 RBL1
23 no phenotypic analysis MP:0003012 10.17 CDKN1A CDKN1B CDKN2A IL2 MDM2 MYC
24 pigmentation MP:0001186 10.02 CDK4 CDKN1B CDKN2A GNAQ MDM2 MYC
25 renal/urinary system MP:0005367 10.02 ABCG2 CDK4 CDKN1A CDKN1B GNAQ MDM2
26 respiratory system MP:0005388 9.93 CCND1 CDKN1A CDKN1B CDKN2A E2F4 GNAQ
27 skeleton MP:0005390 9.8 BRCA2 CCND1 CDKN1A CDKN1B CDKN2A E2F4
28 vision/eye MP:0005391 9.4 CCND1 CDK2 CDK4 CDKN1A CDKN1B CDKN2A

Drugs & Therapeutics for Ocular Cancer

Drugs for Ocular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 278)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
7
Nicotine Approved Phase 4 54-11-5 942 89594
8 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 2,Phase 1,Not Applicable
16 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18 Steroid Synthesis Inhibitors Phase 4
19 Cytochrome P-450 Enzyme Inhibitors Phase 4
20
Hydroxyitraconazole Phase 4
21 Antifungal Agents Phase 4,Phase 2,Phase 1,Not Applicable
22 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
24
Melphalan Approved Phase 3,Phase 1,Phase 2,Not Applicable 148-82-3 4053 460612
25
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
26
Carmustine Approved, Investigational Phase 3,Not Applicable 154-93-8 2578
27
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
28
Topotecan Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 123948-87-8, 119413-54-6 60700
29
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
31
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
32
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
33
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
34
Fotemustine Experimental, Investigational Phase 3
35 Alkylating Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
36 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
37 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
38 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Micronutrients Phase 3,Phase 2
40 Trace Elements Phase 3,Phase 2
41 Anesthetics Phase 3,Phase 2,Not Applicable,Early Phase 1
42 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
43 O(6)-benzylguanine Phase 3,Not Applicable
44 cadexomer iodine Phase 3,Phase 2,Phase 1
45 Anti-Infective Agents, Local Phase 3,Phase 2
46 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
47 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
48 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 295)
# Name Status NCT ID Phase Drugs
1 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4 carboplatin periocular injection;CEV chemotherapy
2 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
4 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
5 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3 carboplatin periocular injection;chemotherapy
6 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
7 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
8 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma Completed NCT00335738 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
9 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
10 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed NCT00079417 Phase 3 carboplatin;vincristine sulfate
11 Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma Recruiting NCT03475121 Phase 3
12 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
13 Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Recruiting NCT01906814 Phase 3 3 cycles chemotherapy;6 cycles chemotherapy
14 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
15 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Active, not recruiting NCT00186888 Phase 3 Vincristine, Carboplatin;Vincristine + Topotecan;Vincristine + Carboplatin + Etoposide;Vincristine + Cyclophosphamide + Doxorubicin;Vincristine+Carboplatin+Etoposide
16 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
17 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
18 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Thiotepa;Vincristine Sulfate
19 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
20 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma Terminated NCT00072384 Phase 3 liposomal vincristine sulfate;carboplatin;etoposide
21 Pain Relief - Tramadol Versus Ibuprofen Unknown status NCT00111046 Phase 1, Phase 2 Ibuprofen;Tramadol
22 Intra-arterial Chemotherapy for Children With Retinoblastoma Unknown status NCT00906113 Phase 1, Phase 2 Intra-arterial injection of melphalan;Injection of melphalan into the ophthalmic artery
23 Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis Unknown status NCT02936388 Phase 2
24 Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Unknown status NCT02874040 Phase 2
25 Efficacy Study of Lucentis in the Treatment of Retinoblastoma Unknown status NCT01899066 Phase 2 Lucentis, chemotherapy;chemotherapy
26 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
27 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
28 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
29 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
30 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
31 Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Unknown status NCT00179920 Phase 2 Carboplatin;VP-16
32 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
33 Study of D-Methadone in Patients With Chronic Pain Completed NCT00588640 Phase 1, Phase 2 d-Methadone;D-methadone;placebo
34 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
35 Melanoma Vaccine With Peptides and Leuprolide Completed NCT00254397 Phase 2 Leuprolide
36 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
37 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
38 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
39 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed NCT01961115 Phase 2 Epacadostat
40 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed NCT01835145 Phase 2 Cabozantinib S-malate;Dacarbazine;Temozolomide
41 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
42 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
43 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
44 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
45 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
46 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
47 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
48 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
49 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
50 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide

Search NIH Clinical Center for Ocular Cancer

Cochrane evidence based reviews: eye neoplasms

Genetic Tests for Ocular Cancer

Anatomical Context for Ocular Cancer

MalaCards organs/tissues related to Ocular Cancer:

41
Eye, Skin, Bone, Lung, Prostate, Bone Marrow, Retina

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Cancer:

19
The Eye

Publications for Ocular Cancer

Articles related to Ocular Cancer:

(show all 17)
# Title Authors Year
1
Antonio Scarpa (1752-1832) and his study on ocular cancer. ( 29552793 )
2018
2
The distinguished Greek born, French ophthalmologist Photinos Panas (1832-1903) and his views on ocular cancer. ( 30003766 )
2018
3
The beginning of using X-rays and the evolution of equipment for the treatment of ocular cancer. ( 28315914 )
2017
4
Views on ocular cancer in Arabo-Islamic medicine and the leading influence of the ancient Greek medicine. ( 27061559 )
2016
5
Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. ( 23441619 )
2013
6
The pathology of ocular cancer. ( 23154492 )
2013
7
Id2 deficiency promotes metastasis in a mouse model of ocular cancer. ( 20127274 )
2010
8
Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells. ( 23181152 )
2010
9
Differential regulation of Dlg1, Scrib, and Lgl1 expression in a transgenic mouse model of ocular cancer. ( 19098995 )
2008
10
A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer. ( 17082795 )
2007
11
Non-cancerous ophthalmic clues to non-ocular cancer. ( 12431692 )
2002
12
Non-ocular cancer in relatives of retinoblastoma patients. ( 2789942 )
1989
13
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. ( 3356485 )
1988
14
Non-ocular cancer in hereditary retinoblastoma survivors and relatives. ( 3587888 )
1987
15
Non-ocular cancer in retinoblastoma survivors. ( 2837050 )
1987
16
Photodynamic therapy of human ocular cancer. ( 2956549 )
1987
17
Recent trends in the treatment of intra-ocular cancer. ( 13790869 )
1960

Variations for Ocular Cancer

Cosmic variations for Ocular Cancer:

9 (show all 45)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1015 RB1 eye,retina,retinoblastoma,NS c.1215+1G>A p.? 13:48373493-48373493 14
2 COSM877 RB1 eye,retina,retinoblastoma,NS c.341C>A p.S114* 13:48342675-48342675 14
3 COSM910 RB1 eye,retina,retinoblastoma,NS c.1467C>A p.C489* 13:48380210-48380210 14
4 COSM5686463 RB1 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 14
5 COSM895 RB1 eye,retina,retinoblastoma,NS c.1363C>T p.R455* 13:48379624-48379624 14
6 COSM943 RB1 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 14
7 COSM13117 RB1 eye,retina,retinoblastoma,NS c.2053C>T p.Q685* 13:48459780-48459780 14
8 COSM891 RB1 eye,retina,retinoblastoma,NS c.958C>T p.R320* 13:48367512-48367512 14
9 COSM1636648 RB1 eye,retina,retinoblastoma,NS c.2106+2T>G p.? 13:48459835-48459835 14
10 COSM1014 RB1 eye,retina,retinoblastoma,NS c.1216-2A>G p.? 13:48376916-48376916 14
11 COSM888 RB1 eye,retina,retinoblastoma,NS c.1666C>T p.R556* 13:48381414-48381414 14
12 COSM938 RB1 eye,retina,retinoblastoma,NS c.967G>T p.E323* 13:48367521-48367521 14
13 COSM878 RB1 eye,retina,retinoblastoma,NS c.751C>T p.R251* 13:48362847-48362847 14
14 COSM887 RB1 eye,retina,retinoblastoma,NS c.1654C>T p.R552* 13:48381402-48381402 14
15 COSM317962 RB1 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 14
16 COSM1026 RB1 eye,retina,retinoblastoma,NS c.2326-2A>C p.? 13:48465203-48465203 14
17 COSM903 RB1 eye,retina,retinoblastoma,NS c.1494T>A p.Y498* 13:48380237-48380237 14
18 COSM1013 RB1 eye,retina,retinoblastoma,NS c.1389+1G>C p.? 13:48379651-48379651 14
19 COSM876 RB1 eye,retina,retinoblastoma,NS c.160G>T p.E54* 13:48307302-48307302 14
20 COSM1030 RB1 eye,retina,retinoblastoma,NS c.1961-1G>A p.? 13:48459687-48459687 14
21 COSM1040 RB1 eye,retina,retinoblastoma,NS c.1960+2T>C p.? 13:48456351-48456351 14
22 COSM890 RB1 eye,retina,retinoblastoma,NS c.409G>T p.E137* 13:48345108-48345108 14
23 COSM911 RB1 eye,retina,retinoblastoma,NS c.1166T>A p.L389* 13:48373443-48373443 14
24 COSM889 RB1 eye,retina,retinoblastoma,NS c.2158A>T p.K720* 13:48463782-48463782 14
25 COSM880 RB1 eye,retina,retinoblastoma,NS c.1333C>T p.R445* 13:48379594-48379594 14
26 COSM3724517 RB1 eye,retina,retinoblastoma,NS c.862-5T>G p.? 13:48364889-48364889 14
27 COSM3724518 RB1 eye,retina,retinoblastoma,NS c.2520+4A>G p.? 13:48473394-48473394 14
28 COSM936 RB1 eye,retina,retinoblastoma,NS c.1183C>T p.Q395* 13:48373460-48373460 14
29 COSM144722 RB1 eye,retina,retinoblastoma,NS c.265-2A>C p.? 13:48342597-48342597 14
30 COSM1047 RB1 eye,retina,retinoblastoma,NS c.982A>C p.N328H 13:48367536-48367536 14
31 COSM942 RB1 eye,retina,retinoblastoma,NS c.2063T>C p.L688P 13:48459790-48459790 14
32 COSM5700369 RB1 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 14
33 COSM1041 RB1 eye,retina,retinoblastoma,NS c.1049+1G>T p.? 13:48367604-48367604 14
34 COSM1017 RB1 eye,retina,retinoblastoma,NS c.380+1G>T p.? 13:48342715-48342715 14
35 COSM3724510 RB1 eye,retina,retinoblastoma,NS c.2527G>T p.E843* 13:48476707-48476707 14
36 COSM1050 RB1 eye,retina,retinoblastoma,NS c.1421G>A p.S474N 13:48380084-48380084 14
37 COSM1016 RB1 eye,retina,retinoblastoma,NS c.1960+1G>A p.? 13:48456350-48456350 14
38 COSM882 RB1 eye,retina,retinoblastoma,NS c.2152G>A p.D718N 13:48463776-48463776 14
39 COSM764 PIK3CA eye,retina,retinoblastoma,NS c.1634A>G p.E545G 3:179218304-179218304 14
40 COSM520 KRAS eye,retina,retinoblastoma,NS c.35G>T p.G12V 12:25245350-25245350 14
41 COSM521 KRAS eye,retina,retinoblastoma,NS c.35G>A p.G12D 12:25245350-25245350 14
42 COSM5700368 eye,retina,retinoblastoma,NS c.2206C>T p.Q736* 13:48463830-48463830 14
43 COSM5686462 eye,retina,retinoblastoma,NS c.1891C>T p.Q631* 13:48456280-48456280 14
44 COSM5668651 eye,retina,retinoblastoma,NS c.2106+1G>T p.? 13:48459834-48459834 14
45 COSM5025108 eye,retina,retinoblastoma,NS c.763C>T p.R255* 13:48362859-48362859 14

Expression for Ocular Cancer

Search GEO for disease gene expression data for Ocular Cancer.

Pathways for Ocular Cancer

Pathways related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F4
2
Show member pathways
14.04 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
3
Show member pathways
13.91 CDK2 CDKN1A CDKN1B CDKN2A E2F4 MDM2
4
Show member pathways
13.9 BRCA2 CCND1 CDK2 CDK4 CDKN1A CDKN1B
5
Show member pathways
13.63 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
6
Show member pathways
13.33 CDK2 CDK4 CDK6 CDKN1A CDKN1B CDKN2A
7
Show member pathways
13.31 CCND1 CDKN1B E2F4 GNAQ IL2 MYC
8
Show member pathways
13.31 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
9
Show member pathways
13.21 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
10
Show member pathways
13.18 CDK2 CDKN1A CDKN1B CDKN2A E2F4 MDM2
11
Show member pathways
13.11 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
12 13.06 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
13
Show member pathways
13.04 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
14
Show member pathways
13.03 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
15
Show member pathways
12.97 CCND1 CDK2 CDK4 CDK6 CDKN1B IL2
16
Show member pathways
12.93 BRCA2 CCND1 CDK2 CDK4 CDKN1A CDKN1B
17
Show member pathways
12.88 CDKN1A CDKN2A MDM2 MYC TP53
18
Show member pathways
12.87 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
19
Show member pathways
12.85 CCND1 CDKN1A CDKN1B IL2 MYC
20 12.77 CCND1 CDK6 CDKN1A CDKN1B CDKN2A MDM2
21
Show member pathways
12.74 CDK2 CDKN1A CDKN1B MDM2 TP53
22 12.73 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
23
Show member pathways
12.71 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
24
Show member pathways
12.7 CCND1 CDKN1B MDM2 MYC RB1 TP53
25 12.7 CCND1 CDK4 CDKN1A CDKN2A IL2 MYC
26 12.7 CCND1 CDK2 CDK4 CDK6 E2F4 MYC
27 12.68 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
28
Show member pathways
12.67 CCND1 MYC POU5F1 SOX2 TP53
29
Show member pathways
12.66 CCND1 CDKN1A CDKN1B MDM2 MYC TP53
30
Show member pathways
12.61 CCND1 CDK2 CDK4 CDK6 CDKN1B RB1
31
Show member pathways
12.59 CCND1 CDKN1A CDKN1B MDM2 MYC TP53
32
Show member pathways
12.59 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
33
Show member pathways
12.55 CCND1 CDK2 CDK4 CDKN1A E2F4 MDM2
34 12.54 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
35
Show member pathways
12.53 E2F4 POU5F1 RB1 SOX2
36
Show member pathways
12.5 CDK2 CDKN1A CDKN1B RB1 TP53
37 12.49 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN2A
38
Show member pathways
12.48 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F4
39 12.45 CCND1 CDKN1A MDM2 MYC TP53
40 12.45 BRCA2 CCND1 CDK2 CDK4 MDM2 MYC
41 12.45 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
42 12.43 CCND1 CDK2 CDK4 CDKN1A CDKN1B E2F4
43 12.41 CDKN1A CDKN1B MDM2 MYC TP53
44
Show member pathways
12.37 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
45 12.36 CCND1 CDKN1A E2F4 MYC TP53
46 12.36 CCND1 CDKN1A E2F4 MYC RBL1 RBL2
47
Show member pathways
12.33 CCND1 CDK2 CDKN1A CDKN1B MDM2 RBL2
48 12.32 CCND1 CDK2 CDK4 CDKN1B IL2 MYC
49
Show member pathways
12.31 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
50 12.3 CCND1 CDKN1A CDKN1B CDKN2A MDM2 MYC

GO Terms for Ocular Cancer

Cellular components related to Ocular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.87 BRCA2 CDK4 CDKN1A CDKN1B MDM2 MYC
2 transcription factor complex GO:0005667 9.8 CDK2 CDK4 E2F4 RB1 RBL1 RBL2
3 nuclear chromatin GO:0000790 9.73 E2F4 MYC POU5F1 TP53
4 chromatin GO:0000785 9.67 CDK4 RB1 RBL1 RBL2
5 nucleoplasm GO:0005654 9.55 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
6 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.35 CCND1 CDK2 CDK4 CDK6 CDKN1A
7 cytoplasm GO:0005737 10.3 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
8 cytosol GO:0005829 10.22 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
9 nucleus GO:0005634 10.13 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
10 nucleolus GO:0005730 10.02 CDK4 CDKN1A CDKN2A MDM2 MYC RBL2

Biological processes related to Ocular Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 CDK4 CDK6 CDKN1B E2F4
2 regulation of gene expression GO:0010468 9.99 CDK4 CDK6 MDM2 MYC POU5F1 SOX2
3 negative regulation of cell growth GO:0030308 9.96 CDKN1A CDKN1B CDKN2A TP53
4 response to estradiol GO:0032355 9.95 BRCA2 CCND1 CDKN1B MYC
5 negative regulation of epithelial cell proliferation GO:0050680 9.91 CDK6 CDKN1B RB1 SOX2
6 regulation of cell cycle GO:0051726 9.91 CCND1 CDK2 CDK4 E2F4 RB1 RBL1
7 response to organic substance GO:0010033 9.9 CCND1 CDK4 CDKN1A
8 negative regulation of protein kinase activity GO:0006469 9.89 CDKN2A GNAQ RB1
9 regulation of signal transduction by p53 class mediator GO:1901796 9.89 CDK2 MDM2 TP53
10 response to wounding GO:0009611 9.88 MYC POU5F1 SOX2
11 cellular response to organic cyclic compound GO:0071407 9.88 CDKN1B MDM2 MYC
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.88 CDKN1A RB1 RBL1 RBL2
13 positive regulation of fibroblast proliferation GO:0048146 9.88 CDK4 CDK6 CDKN1A MYC
14 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.86 CCND1 CDKN1A CDKN1B
15 cell cycle arrest GO:0007050 9.86 CDK6 CDKN1A CDKN1B CDKN2A MYC RB1
16 animal organ regeneration GO:0031100 9.85 CCND1 CDK4 CDKN1A
17 negative regulation of cell cycle GO:0045786 9.85 CDK6 CDKN1B RB1
18 Ras protein signal transduction GO:0007265 9.85 CDK2 CDKN1A CDKN2A RB1 TP53
19 response to gamma radiation GO:0010332 9.83 BRCA2 MYC TP53
20 positive regulation of cell cycle GO:0045787 9.83 CCND1 CDK4 CDKN1B MDM2 MYC
21 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.81 CDKN1A CDKN1B CDKN2A
22 negative regulation of cell cycle arrest GO:0071157 9.81 CCND1 CDK4 MDM2
23 response to X-ray GO:0010165 9.8 BRCA2 CCND1 CDKN1A
24 regulation of mitotic cell cycle GO:0007346 9.8 CDKN1A MYC RB1 RBL1 RBL2
25 negative regulation of phosphorylation GO:0042326 9.79 CDKN1A CDKN1B CDKN2A
26 replicative senescence GO:0090399 9.77 CDKN1A CDKN2A TP53
27 cell cycle GO:0007049 9.77 BRCA2 CCND1 CDK2 CDK4 CDK6 CDKN1A
28 response to hyperoxia GO:0055093 9.72 CDK4 CDKN1A
29 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.72 BRCA2 TP53
30 response to magnesium ion GO:0032026 9.72 CCND1 MDM2
31 mitotic G1 DNA damage checkpoint GO:0031571 9.72 CCND1 CDK2 TP53
32 cellular response to antibiotic GO:0071236 9.71 CDKN1B MDM2
33 amyloid fibril formation GO:1990000 9.71 CDKN2A MDM2
34 regulation of cell division GO:0051302 9.7 RBL1 RBL2
35 negative regulation of monocyte differentiation GO:0045656 9.7 CDK6 MYC
36 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.7 CDK4 CDK6 CDKN2A
37 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.7 CDK2 CDKN1A CDKN1B E2F4 MDM2 RBL2
38 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.69 CDK4 MYC
39 re-entry into mitotic cell cycle GO:0000320 9.69 CCND1 MYC
40 endodermal cell fate specification GO:0001714 9.68 POU5F1 SOX2
41 signal transduction by p53 class mediator GO:0072331 9.68 CDKN1A TP53
42 negative regulation of cyclin-dependent protein kinase activity GO:1904030 9.67 CDKN1A CDKN1B
43 regulation of lipid kinase activity GO:0043550 9.67 RB1 RBL1 RBL2
44 cellular response to actinomycin D GO:0072717 9.66 MDM2 TP53
45 G1/S transition of mitotic cell cycle GO:0000082 9.28 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
46 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 CDKN2A E2F4 IL2 MYC POU5F1 RB1
47 positive regulation of transcription, DNA-templated GO:0045893 10.16 BRCA2 CDK2 CDKN2A MYC RB1 SOX2
48 negative regulation of apoptotic process GO:0043066 10.14 CDKN1A CDKN1B IL2 MDM2 MYC TP53
49 positive regulation of cell proliferation GO:0008284 10.14 CCND1 CDK2 CDK4 CDKN1B IL2 MDM2
50 cellular response to DNA damage stimulus GO:0006974 10.12 BRCA2 CCND1 CDK2 CDKN1A MYC TP53

Molecular functions related to Ocular Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 ABCG2 BRCA2 CCND1 CDK2 CDK4 CDK6
2 protein kinase binding GO:0019901 9.93 CCND1 CDKN1A CDKN1B CDKN2A TP53
3 protein-containing complex binding GO:0044877 9.88 CCND1 CDK4 CDKN1A CDKN1B MYC
4 ubiquitin protein ligase binding GO:0031625 9.85 CDKN1A MDM2 POU5F1 RB1 TP53
5 proximal promoter DNA-binding transcription repressor activity, RNA polymerase II-specific GO:0001078 9.81 E2F4 RB1 RBL1 RBL2
6 transcription factor binding GO:0008134 9.7 CCND1 CDKN2A E2F4 MYC RB1 RBL1
7 RNA polymerase II activating transcription factor binding GO:0001102 9.67 RB1 RBL1 RBL2
8 promoter-specific chromatin binding GO:1990841 9.67 E2F4 RBL1 RBL2 TP53
9 disordered domain specific binding GO:0097718 9.62 CDKN2A MDM2 RB1 TP53
10 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.61 CDKN1A CDKN1B CDKN2A
11 RNA polymerase II regulatory region DNA binding GO:0001012 9.58 RB1 RBL1 RBL2
12 cyclin binding GO:0030332 9.56 CDK2 CDK4 CDK6 CDKN1B
13 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.1 CCND1 CDK2 CDK4 CDK6 CDKN1A CDKN1B
14 DNA binding GO:0003677 10.18 BRCA2 CDKN2A E2F4 MYC POU5F1 RB1
15 DNA-binding transcription factor activity GO:0003700 10.02 E2F4 MYC POU5F1 RB1 SOX2 TP53

Sources for Ocular Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....